Safety, Efficacy, and Purity

Published Study, The Open Natural Products Journal (2010)

An Initial Evaluation of the Safety, Efficacy and Purity of VigRX™ is a peer-reviewed study published in The Open Natural Products Journal (2010) by researchers from AIBMR Life Sciences, Mae Fah Luang University, Natural Remedies, and Flora Research Laboratories. It represents the most comprehensive single evaluation of VigRX to date, combining purity analysis, mechanism-of-action research, and two separate animal efficacy trials within one rigorously designed study.

Study Design

Two trials were conducted in Sprague-Dawley rats: a short-term 14-day study (n=10 per group) at 15 and 30 mg/kg/day, and a long-term 12-week study (n=12 per group) at 15 mg/kg/day. Sexual behavior, erect penile size, intracavernous pressure (ICP), sperm concentration, testosterone, organ weights, blood chemistry, and histopathology were all assessed.

Key Efficacy Results — 14-Day Study (30 mg/kg/day)

At the higher dose, VigRX produced statistically significant improvements across every measured sexual health parameter. Intracavernous pressure — a direct physiological measure of erection quality — rose from 49.70 mmHg in controls to 83.56 mmHg in treated rats (p<0.01). Ejaculation frequency more than doubled (1.25 vs. 3.14, p<0.05), intromission frequency increased by 88% (19.0 vs. 35.71, p<0.05), and erect penile width and length both improved significantly. Ejaculation latency decreased from 954 seconds in controls to 539 seconds (p<0.05), and intromission latency dropped from 345 seconds to 109 seconds (p<0.001).

Key Efficacy Results — 12-Week Study (15 mg/kg/day)

Over the extended trial, VigRX produced a statistically significant 69% increase in serum testosterone — from 3.66 ng/mL in the control group to 6.20 ng/mL in treated rats (p<0.05). Intracavernous pressure remained significantly elevated (85.75 mmHg vs. 58.08 mmHg in controls, p<0.05), and sperm concentration increased significantly (24.57 vs. 20.41 ×10⁶/mL, p<0.05). A significant reduction in ejaculation latency was also observed.

Safety Profile

No significant histopathological changes were found in any tissue — including liver, kidney, and testes — across either study. Blood chemistry markers including glucose, creatinine, BUN, cholesterol, triglycerides, ALT, AST, and alkaline phosphatase all remained within normal ranges throughout the 12-week trial. A minor, non-dose-dependent reduction in liver and kidney weight was observed in the 14-day study but did not persist at 12 weeks, and no corresponding histopathological changes were found, indicating no clinically meaningful safety concern.

Conclusion

This study provides strong peer-reviewed evidence that VigRX is both effective and safe. It significantly enhances key markers of male sexual wellness — including erection quality, sexual drive, testosterone, and sperm production — without adverse effects on organs or systemic health. These findings justify VigRX's position as one of the most evidence-backed herbal sexual wellness formulations available.

Click here to read the full report →
Explore the complete VigRX product line →